Biogen Financial Ratios
BIIB / Health Care|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Cash-backed earnings: Operating cash flow exceeds net income
- Altman Z-Score 1.75 (gray zone, between 1.23 and 2.9)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
7.1%
ROE ranks in the below average among Health Care companies
Profit Margin
13.1%
Net Income / Revenue
Asset Turnover
0.34
Revenue / Total Assets
Equity Multiplier
1.61
Total Assets / Equity
Composite: 7.1% (reported: 7.1%)
Profitability
Gross Margin
-
Operating Margin
-
EBITDA
$2.6B
EBITDA Margin
26.3%
Liquidity
Current Ratio
2.68
Quick Ratio
2.03
Solvency
Interest Coverage
8.24
Efficiency
Asset Turnover
0.34
Inventory Turnover
1.11
Days Sales Outstanding
50 days
As of FY2025 · SEC 10-K Annual Filings · Updated Mar 3, 2026
Earnings Quality
Accrual Ratio
-3.2%
+1.3pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.